Targeting the small airways asthma phenotype: if we can reach it, should we treat it?
- 30 April 2013
- journal article
- review article
- Published by Elsevier BV in Annals of Allergy, Asthma & Immunology
- Vol. 110 (4), 233-239
- https://doi.org/10.1016/j.anai.2013.02.009
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add‐on therapyBritish Journal of Clinical Pharmacology, 2012
- 1-year prospective real life monitoring of asthma control and quality of life in ItalyRespiratory Research, 2012
- The Utility of Forced Expiratory Flow between 25% and 75% of Vital Capacity in Predicting Childhood Asthma Morbidity and SeverityJournal of Asthma, 2012
- Relating small airways to asthma control by using impulse oscillometry in childrenJournal of Allergy and Clinical Immunology, 2011
- Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: A preliminary studyAllergy and Asthma Proceedings, 2011
- Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthmaAllergy and Asthma Proceedings, 2010
- Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD PatientsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Effects of extra‐fine inhaled beclomethasone/formoterol on both large and small airways in asthmaAllergy, 2010
- In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti‐static spacers and a metered dose inhalerBritish Journal of Clinical Pharmacology, 2009
- Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBritish Journal of Clinical Pharmacology, 2001